Corporate Leadership
James R. Sulat
Chief Executive Officer & Chief Financial Officer
Mr. Sulat has served as the Company’s Chief Executive Officer and Chief
Financial Officer since October 2009 and has served as a director since October
2003. From February 2008 to November 2008, Mr. Sulat served as the Chief
Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company.
From May 2005 to February 2008, Mr. Sulat served as Chief Executive Officer of
Memory Pharmaceuticals Corp. Mr. Sulat was Senior Executive Vice President and
Interim Chief Financial Officer of R.R. Donnelley & Sons Co., a diversified
printing company, from February 2004 until May 2004. From April 2003 to
February 2004, Mr. Sulat was Senior Executive Vice President of Moore Wallace
Incorporated, a diversified printing company that was acquired by R.R.
Donnelley in 2004. From April 1998 to April 2003, Mr. Sulat was Vice President
and Chief Financial Officer of Chiron Corporation, a biotechnology company. Mr.
Sulat is also a director of Intercell AG and Momenta Pharmaceuticals, Inc., and
has previously served as a director of Memory Pharmaceuticals Corp. and Vans,
Inc. Mr. Sulat holds a B.S. from Yale University, an M.B.A. from Stanford
University and an M.S. in health services administration from Stanford
University.
John Borkholder
General Counsel & Secretary
Mr.
Borkholder has served as General Counsel & Secretary since January 2011.
Mr. Borkholder joined Maxygen in November 2005 as Senior Counsel and served as
Chief Corporate Counsel & Secretary beginning in March 2008 before being
promoted to General Counsel in January 2011. Prior to joining Maxygen, Mr.
Borkholder served as an attorney with the law firms of Orrick, Herrington &
Sutcliffe LLP and Giancarlo & Gnazzo, P.C. Mr. Borkholder holds a B.A. in
philosophy from the University of North Carolina at Wilmington and a J.D. from
the University of California, Hastings College of the Law.
Board of Directors
Isaac Stein
Executive Chairman of the Board
Mr.
Stein has served as the Company’s Chairman of the Board of Directors since June
1998 and as Executive Chairman of the Board of Directors since September 2009,
and has been a director since May 1996. Since November 1982, Mr. Stein has been
President of Waverley Associates, Inc., a private investment firm. He is a
member of and the emeritus Chairman of the Board of Trustees of Stanford
University and is a director of American Balanced Fund, Inc., International
Growth and Income Fund, Inc. and The Income Fund of America, Inc. (all
affiliated with the Capital Group Companies), and Alexza Pharmaceuticals, Inc.
He is also a director of the James Irvine Foundation. Mr. Stein received an
M.B.A. and J.D. from Stanford University and a B.A. in mathematical economics
from Colgate University.
Louis G. Lange,
M.D., Ph.D., has served as a director since December 2005. Dr. Lange is currently
a partner with Asset Management Company, a venture capital firm that he joined
in June 2009. Since June 2009, Dr. Lange has also served as a Senior Advisor of
Gilead Sciences, Inc. From April 2009 to June 2009, Dr. Lange served as
Executive Vice President, Cardiovascular Therapeutics, of Gilead. He was a
founder of CV Therapeutics, Inc. and served as its Chairman and Chief Executive
Officer from August 1992 until the acquisition of the company by Gilead in
April 2009. Dr. Lange has served as a trustee on the University of Rochester
Board of Trustees since May 1997 and was a member of the governing body of the
Emerging Company Section of the Biotechnology Industry Organization from 1999
to 2009. From 1980 to 1992, Dr. Lange served on the faculty of Washington
University School of Medicine, including as Chief of Cardiology at Jewish
Hospital in St. Louis, Missouri from 1985 to 1992, and as a full Professor of
Medicine from 1990 until 1992. Dr. Lange holds an M.D. from Harvard Medical School
and a Ph.D. in biological chemistry from Harvard University.
Kenneth B. Lee,
Jr.
has served as a director since September 2009. He is currently a General
Partner with Hatteras Venture Partners, LLC (formerly, BioVista Capital, LLC),
which he joined in 2003. From January 2002 to June 2002, Mr. Lee served as
President of A.M. Pappas & Associates, an international life sciences
venture development company. From 2000 to 2001, Mr. Lee was Managing Director
of Ernst & Young LLP’s Health Sciences Corporate Finance Group. From 1982
through 2000, Mr. Lee was a Partner of Ernst & Young LLP. Mr. Lee is also a
director of Inspire Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., and Pozen, Inc. and has previously
served as a director of Abgenix, Inc., OSI Pharmaceuticals and CV Therapeutics,
Inc. Mr. Lee also serves as a member of the executive committee of the Board of
the North Carolina Biotechnology Industry Organization. Mr. Lee received a B.A.
from Lenoir-Rhyne College and an M.B.A. from the University of North Carolina
at Chapel Hill.
Ernest Mario,
Ph.D.,
has served as a director since July 2001. Since August 2007, Dr. Mario has
served as the Chairman of the Board and Chief Executive Officer of Capnia,
Inc., a privately held pharmaceutical company. From April 2003 to August 2007,
Dr. Mario served as the Chairman of the Board and Chief Executive Officer of
Reliant Pharmaceuticals, Inc., a privately held pharmaceutical company. Prior
to joining Reliant Pharmaceuticals, he was Chairman and Chief Executive Officer
of IntraBiotics Pharmaceuticals, Inc., a biopharmaceutical company, and its
predecessor Apothogen, Inc. from January 2002 until April 2003. Dr. Mario was
the Chairman and Chief Executive Officer of ALZA Corporation, a pharmaceutical
company, from 1997 to 2001 and was Co-Chairman and Chief Executive Officer of
ALZA Corporation from 1993 to 1997. Prior to joining ALZA, Dr. Mario served as
Chief Executive Officer of Glaxo Holdings plc, a pharmaceutical company, from
1989 to 1993, and as Deputy Chairman from 1992 to 1993. Dr. Mario is also a
director of Pharmaceutical Product Development, Inc. Celgene Corporation and
Boston Scientific Corporation and has previously served as a director of
IntraBiotics Pharmaceuticals, Inc. Dr. Mario received a Ph.D. and an M.S. in
physical sciences from the University of Rhode Island and a B.S. in pharmacy
from the Ernest Mario School of Pharmacy at Rutgers University.
Gordon Ringold,
Ph.D.,
has served as a director since September 1997. Since June 2010, Dr. Ringold has
served as the Senior Director of the University of California, Santa Cruz,
Silicon Valley Initiatives. Since June 2010, Dr. Ringold also has served as the
Executive Chairman of Alavita Pharmaceuticals, Inc., a private biotechnology
company. Dr. Ringold previously served as the Chairman and Chief Executive
Officer of that company from 2005 to June 2010. From 1997 to 2005, Dr. Ringold
served as Chairman and Chief Executive Officer of SurroMed, Inc., a
biotechnology company focused on novel clinical databases. From March 1995 to
February 2000, Dr. Ringold was Chief Executive Officer and Scientific Director
of Affymax Research Institute where he managed the development of novel
technologies to accelerate the pace of drug discovery. Before serving as Chief
Executive Officer of Affymax, Dr. Ringold was the President and Scientific
Director of Affymax Research Institute. Dr. Ringold is also a director of
Alexza Pharmaceuticals, Inc. Dr. Ringold received a Ph.D. in microbiology from
the University of California, San Francisco in the laboratory of Dr. Harold
Varmus before joining the Stanford University School of Medicine, Department of
Pharmacology. Dr. Ringold also received a B.S. in biology from the University
of California, Santa Cruz.
James R. Sulat’s
biography is set forth above.
Return to About Maxygen
|
